Corbus Pharmaceuticals Holdings (STU:3371) Moat Score: 2/10 (As of Jul. 09, 2026)


STU:3371 Corbus Pharmaceuticals Holdings Inc STU:3371
31 GF Score
Price €8.36
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Moat Score?

Corbus Pharmaceuticals Holdings STU:3371 +1.40% 31 Moat Score is 2 as of Jul. 09, 2026. GuruFocus rates STU:3371 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,394 Biotechnology companies, Corbus Pharmaceuticals Holdings ranks better than 58.32% on this metric.

Corbus Pharmaceuticals Holdings has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Corbus Pharmaceuticals Holdings has No Moat: Corbus Pharmaceuticals has limited market leadership and lacks significant customer switching costs. While it holds some intellectual property, the competitive pharmaceutical landscape and lack of strong brand strength or regulatory barriers result in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Corbus Pharmaceuticals Holdings might have No Moat - Very weak/transient advantages.

Corbus Pharmaceuticals Holdings  (STU:3371) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Corbus Pharmaceuticals Holdings Moat Score Related Terms

STU:3371 vs PRQR, NRXP, CRBU: Moat Score Comparison

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corbus Pharmaceuticals Holdings Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Moat Score falls into.


STU:3371
31GF Score
Corbus Pharmaceuticals Holdings Inc STU:3371
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Corbus Pharmaceuticals Holdings (STU:3371) has a Moat Score of 2 as of Jul. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Corbus Pharmaceuticals Holdings ranks #581 out of 1394 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Corbus Pharmaceuticals Holdings' Moat Score too high?
Corbus Pharmaceuticals Holdings' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Corbus Pharmaceuticals Holdings' value of 2 is 0% at this industry median. Based on the distribution chart, Corbus Pharmaceuticals Holdings ranks #581 out of 1394 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Moat Score compare to PRQR and NRXP?
According to the Biotechnology industry distribution chart, Corbus Pharmaceuticals Holdings ranks #581 out of 1394 companies for Moat Score. This puts Corbus Pharmaceuticals Holdings in the upper half of its industry. The industry median Moat Score is 2.00. Corbus Pharmaceuticals Holdings' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corbus Pharmaceuticals Holdings's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corbus Pharmaceuticals Holdings's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Corbus Pharmaceuticals Holdings (STU:3371) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Corbus Pharmaceuticals Holdings' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (STU:3371), the current Moat Score is 2 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score

Get the complete analysis for STU:3371

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.36
Price